Opioid-Induced Hyperalgesia a Qualitative Systematic Review Martin S

Total Page:16

File Type:pdf, Size:1020Kb

Opioid-Induced Hyperalgesia a Qualitative Systematic Review Martin S Anesthesiology 2006; 104:570–87 © 2006 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Opioid-induced Hyperalgesia A Qualitative Systematic Review Martin S. Angst, M.D.,* J. David Clark, M.D., Ph.D.† Opioids are the cornerstone therapy for the treatment of an all-inclusive and current overview of a topic that may moderate to severe pain. Although common concerns regard- be difficult to grasp as a whole because new evidence ing the use of opioids include the potential for detrimental side accumulates quickly and in quite distinct research fields. effects, physical dependence, and addiction, accumulating evi- dence suggests that opioids may yet cause another problem, As such, a comprehensive review may serve as a source often referred to as opioid-induced hyperalgesia. Somewhat document. However, a systematic review also uses a paradoxically, opioid therapy aiming at alleviating pain may framework for presenting information, and such a frame- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/104/3/570/360792/0000542-200603000-00025.pdf by guest on 01 October 2021 render patients more sensitive to pain and potentially may work may facilitate and clarify future communication by aggravate their preexisting pain. This review provides a com- clearly delineating various entities or aspects of OIH. prehensive summary of basic and clinical research concerning opioid-induced hyperalgesia, suggests a framework for organiz- Finally, a systematic review aims at defining the status ing pertinent information, delineates the status quo of our quo of our knowledge concerning OIH, a necessary task knowledge, identifies potential clinical implications, and dis- to guide future research efforts and to identify potential cusses future research directions. clinical implications. For the purpose of this review, it is important to point OPIOIDS are the cornerstone therapy for alleviating out that OIH occurs in several distinct settings charac- moderate to severe pain. Whereas opioids have long terized by the opioid dose administered and the pattern been used for alleviating acute and cancer-related pain, of administration. Most work reported OIH during ongo- they recently have gained significant popularity for the ing (maintenance) therapy or withdrawal from opioids. treatment of chronic nonmalignant pain. Today, opioids Other bodies of literature documented OIH while admin- are second only to nonsteroidal antiinflammatory drugs istering either very high or very low opioid doses. Al- in terms of prescription frequency for chronic pain.1 though the opioid dose offers a convenient way to cat- Common concerns regarding the use of opioids are the egorize different types of OIH, it is less certain to what potential for detrimental side effects, physical depen- degree these phenomenological differences are mirrored dence, and addiction. However, recent research sug- by distinct mechanisms. Nevertheless, in this review we gests that opioids may yet cause another problem, often use separate sections to discuss OIH in the context of (1) referred to as opioid-induced hyperalgesia (OIH). Pa- maintenance dosing and withdrawal, (2) at very high or tients receiving opioids to control their pain somewhat escalating doses, and (3) at ultra-low doses. Each section paradoxically may become more sensitive to pain as a is divided further into a human and animal/basic science direct result of opioid therapy. That is, the use of opioids data subsection. At the end of each section, we draw may be a double-edged sword. They provide straight conclusions and outline potential clinical implications. analgesic and antihyperalgesic effects initially, but sub- The review ends with a discussion of future research sequently are associated with the expression of hyperal- directions. gesia likely reflecting upregulation of compensatory pronociceptive pathways. Several recent articles have reviewed and highlighted Literature Search important aspects of OIH, which reflects the growing Strategy interest and rapidly expanding body of literature regard- The three major databases, PubMed, BIOSIS, and Psy- 2–5 ing this phenomenon. The aim of this article is to cInfo, were searched for identifying articles pertinent to provide a comprehensive and systematic review of the OIH. PubMed, BIOSIS, and PsycInfo index publications literature pertinent to OIH. The primary intent of such relating to human health, the biologic and biomedical an undertaking is to provide the interested reader with sciences, and the field of psychology, respectively. The search included all work published between the incep- * Assistant Professor, Department of Anesthesia, Stanford University School of tion of a database (PubMed, 1966; BIOSIS, 1969; Psy- Medicine, Stanford, California; † Associate Professor, Department of Anesthesia, cInfo, 1887) and September 2004. Stanford University School of Medicine, Stanford, California, and Veterans Affairs Palo Alto Health Care System, Palo Alto, California. PubMed. Ideally, a search in PubMed using the mesh Received from the Department of Anesthesia, Stanford University School of terms hyperalgesia/chemically induced AND analge- Medicine, Stanford, California. Submitted for publication April 22, 2005. Ac- sics, opioid would have retrieved most of the relevant cepted for publication September 19, 2005. Support was provided solely from institutional and/or departmental sources. articles. However, such a search missed important arti- Address correspondence to Dr. Angst: Department of Anesthesia, Stanford cles when comparing results with an a priori index of all University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5117. [email protected]. Individual article reprints may be purchased through the relevant articles known to the authors. A more complex Journal Web site, www.anesthesiology.org. search accounting for variations in indexing was neces- Anesthesiology, V 104, No 3, Mar 2006 570 OPIOID-INDUCED HYPERALGESIA 571 sary to retrieve most of the pertinent articles without fects. Other articles were excluded because they re- listing an abundance of irrelevant publications. The final ported data obtained in nonmammalian species (lizards), search in PubMed was based on four “hedges” of free- hyperalgesia as a consequence of abstinence from en- text terms and medical subject headings. Hedges one dogenous opioids, or antianalgesic rather than hyperal- and two, and hedges three and four were combined for gesic treatment effects (attenuation of analgesic effects the search. Title rather than title/abstract searches were rather than increased sensitivity to pain). used to minimize retrieval of irrelevant citations. The The 139 articles included in this review were supple- hedges were as follows: mented by an additional 41 publications. These 41 arti- cles were added because they were either identified by ● Hedge 1 (induced hyperalgesia): hyperalgesia/chemi- the authors as containing relevant data when they re- cally induced [mesh] OR hyperalgesia/etiology OR an- viewed references cited in retrieved manuscripts, or tianalges* OR ((allodyni* [ti] OR hyperesthesi* [ti] OR these articles provided important background informa- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/104/3/570/360792/0000542-200603000-00025.pdf by guest on 01 October 2021 hyperalg* [ti]) AND (produc* [ti] OR elicit* [ti] OR tion indirectly related to OIH. Specifically, 18 manu- cause* [ti] OR trigger* [ti] OR refer* [ti] OR induc* scripts provided additional data relevant for the discus- [ti])); sion of hyperalgesia associated with the exogenous ● Hedge 2 (opioids): opioid* [ti] OR opiate* [ti] OR administration of opioids (2 manuscripts in nonmammal morphine [ti] OR fentanyl [ti]) OR analgesics, opioid species but of particular interest), 7 articles reported [pa] OR “opioid-related disorders”[mesh] OR “recep- analgesic effects in the context of opioid-antagonist ad- tors, opioid”[mesh] OR “analgesics, opioid”[mesh]; ministration, 8 articles documented mechanisms poten- ● Hedge 3 (drug tolerance or withdrawal): (toler* [ti] OR tially related to OIH but without testing for the expres- withdrawal [ti] OR adapt* [ti]) OR “substance with- sion of OIH, 7 manuscripts were reviews of topics drawal syndrome”[mesh] OR “drug tolerance”[mesh] pertinent to the discussion of OIH, and 1 reference OR “adaptation, physiologic”[mesh]; referred to a diagnostic guidebook. The 157 articles ● Hedge 4 (increased sensitivity to pain or sensation): reporting OIH in the context of exogenous opioid ad- hyperalgesia [mesh] OR hyperalges* OR allodyni* OR ministration consist of 120 animal and 37 human studies. hyperesthesi*. Biosis. Variability in indexing required combing three OIH during Maintenance and Withdrawal hedges: Human Studies ● Hedge 1 (title search): ((opiate* OR opioid* OR heroin Brief Historical Perspective. For more than a cen- OR fentanyl OR morphine) AND (antianalges* OR allo- tury, clinical reports have listed hyperesthesia or an dyni* OR hyperesthesi* OR hyperalg*)) NOT (antihy- increased sensitivity to pain as one of the symptoms peralges* OR “anti hyperalges*”)); associated with opioid withdrawal. In an essay dating ● Hedge 2 (subject search): hyperalgesia AND drug-in- back to 1880, Rossbach wrote, “[W] hen dependence on duced; opioids finally becomes an illness of itself, opposite ef- ● Hedge 3 (subject search): ((hyperalgesia AND (opiate* fects like restlessness, sleep disturbance, hyperesthesia, OR opioid*)). neuralgia and irritability become manifest.”6
Recommended publications
  • Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
    SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use.
    [Show full text]
  • Opioid Tolerance in Methadone Maintenance Treatment: Comparison
    Gutwinski et al. Harm Reduction Journal (2016) 13:7 DOI 10.1186/s12954-016-0095-0 RESEARCH Open Access Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment Stefan Gutwinski*, Nikola Schoofs, Heiner Stuke, Thomas G. Riemer, Corinde E. Wiers and Felix Bermpohl Abstract Background: This study aimed to investigate the development of opioid tolerance in patients receiving long-term methadone maintenance treatment (MMT). Methods: A region-wide cross-sectional study was performed focusing on dosage and duration of treatment. Differences between racemic methadone and levomethadone were examined. All 20 psychiatric hospitals and all 110 outpatient clinics in Berlin licensed to offer MMT were approached in order to reach patients under MMT fulfilling the DSM IV criteria of opiate dependence. In the study, 720 patients treated with racemic methadone or levomethadone gave information on the dosage of treatment. Out of these, 679 patients indicated the duration of MMT. Results: Treatment with racemic methadone was reported for 370 patients (54.5 %), with levomethadone for 309 patients (45.5 %). Mean duration of MMT was 7.5 years. We found a significant correlation between dosage and duration of treatment, both in a conjoint analysis for the two substances racemic methadone and levomethadone and for each substance separately. These effects remained significant when only patients receiving MMT for 1 year or longer were considered, indicating proceeding tolerance development in long-term treatment. When correlations were compared between racemic methadone and levomethadone, no significant difference was found. Conclusions: Our data show a tolerance development under long-term treatment with both racemic methadone and levomethadone.
    [Show full text]
  • Clinical and Pharmacokinetic Evaluation of S
    Casoni et al. Acta Veterinaria Scandinavica (2015) 57:21 DOI 10.1186/s13028-015-0112-4 RESEARCH Open Access Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration Daniela Casoni1*, Claudia Spadavecchia1, Beat Wampfler2, Wolfgang Thormann3 and Olivier L Levionnois1 Abstract Background: Intravenous anaesthetic drugs are the primary means for producing general anaesthesia in equine practice. The ideal drug for intravenous anaesthesia has high reliability and pharmacokinetic properties indicating short elimination and lack of accumulation when administered for prolonged periods. Induction of general anaesthesia with racemic ketamine preceded by profound sedation has already an established place in the equine field anaesthesia. Due to potential advantages over racemic ketamine, S-ketamine has been employed in horses to induce general anaesthesia, but its optimal dose remains under investigation. The objective of this study was to evaluate whether 2.5 mg/kg S-ketamine could be used as a single intravenous bolus to provide short-term surgical anaesthesia in colts undergoing surgical castration, and to report its pharmacokinetic profile. Results: After premedication with romifidine and L-methadone, the combination of S-ketamine and diazepam allowed reaching surgical anaesthesia in the 28 colts. Induction of anaesthesia as well as recovery were good to excellent in the majority (n = 22 and 24, respectively) of the colts. Seven horses required additional administration of S-ketamine to prolong the duration of surgical anaesthesia. Redosing did not compromise recovery quality. Plasma concentration of S-ketamine decreased rapidly after administration, following a two-compartmental model, leading to the hypothesis of a consistent unchanged elimination of the parent compound into the urine beside its conversion to S-norketamine.
    [Show full text]
  • RMP Levopidon
    VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Levomethadone is indicated as substitution therapy for maintenance of opioid dependence in adults in conjunction with appropriate medical, social and psychosocial care. Opioid users entering specialist treatment are on average 33 years old, with female patients being younger in most countries. Across Europe, male opioid clients outnumber their female counterparts by a ratio of about three to one. The great majority of opioid clients report having started to use the drug before the age of 30, with almost half (46 %) of all opioid clients having done so before the age of 20. In general, opioid users report higher levels of homelessness and unemployment and lower levels of education than primary users of other drugs, and they are usually concentrated in urban areas. Source: EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) 2012 Annual report on the state of the drugs problem in Europe http://www.emcdda.europa.eu/publications/annual-report/2012 VI.2.2 Summary of treatment benefits Levomethadone reduces withdrawal symptoms in people addicted to heroin or other narcotic drugs without causing the “high” associated with the drug addiction. Levomethadone treatment is an integral part of detoxification and maintenance programs in case of opioid addiction. There are several relevant objectives of levomethadone maintenance therapy: to suppress signs and symptoms of opioid withdrawal, to extinguish opioid-drug craving, and to block the reinforcing effects of illicit opioids. Each of these objectives is accomplished in phases, rather than at once, relying on the administration of adequate levomethadone doses to achieve and sustain optimum blood levels.
    [Show full text]
  • HPLC Enantioseparation of Tramadol and Its Metabolites: Method Validation and Application to Environmental Samples
    HPLC enantioseparation of Tramadol and its metabolites: method validation and application to environmental samples Cátia Sofia Rodrigues Silva Master in Quality Control Faculty of Pharmacy of University of Porto 2016 Separação enantiomérica por HPLC do Tramadol e seus metabolitos: validação do método e aplicação em amostras ambientais Cátia Sofia Rodrigues Silva Dissertação do 2º Ciclo de Estudos Conducente ao Grau de Mestre em Controlo de Qualidade – especialização em Ambiente Trabalho realizado sob a orientação do Professor Doutor Carlos Manuel Magalhães Afonso e Professora Doutora Maria Elizabeth Tiritan 2016 De acordo com a legislação em vigor, não é permitida a reprodução de qualquer parte desta dissertação/tese HPLC enantioseparation of tramadol and metabolites: method validation and application to environmental samples ACKNOWLEDGEMENTS I would like to thank to Prof. Dr. Carlos Afonso, my supervisor, and Prof.ª Dr.ª Maria Elizabeth Tiritan, my co-supervision, for all the support, patience and dedication during the realization of this seminar and the experimental work. Your unconditional support was very important to me and it was certainly a privilege to work with you and acquire all knowledge you have given to me. To Prof.ª Dr.ª Cláudia Ribeiro, to Master Alexandra Maia, PhD Student, and to Master Virgínia Gonçalves, Superior technical of IINFACTS, I would like to thank for all the support that given me in experimental work, over this year, and for all the attention and availability in the laboratory’s work. To my parents, my family and my friends which have a lot of patience for me and make me laugh in the certain time.
    [Show full text]
  • Opioid-Induced Hyperalgesia (OIH)
    Opioid-Induced Hyperalgesia (OIH) Brian Johnson M.D. Assoc Prof Psychiatry and Anesthesia SUNY Upstate Medical University Disclosures • Research on shifts in the hypothalamic- pituitary-adrenal system and depression during and after alcohol withdrawal sponsored by the Distilled Spirits Council of the United States (Johnson 1986) Learning Objectives 1. Get the “big picture” about why opioid prescribing has accelerated recently, setting the environment for OIH to be commonplace 2. Know the definition of OIH 3. Know the neural mechanisms of OIH 4. Know the effect of methadone or buprenorphine maintenance on OIH Learning Objectives 2 5. Know how long it takes to induce OIH 6. Know what to do about OIH; with addicted patients and non-addicted patients 7. Understand the surgical pain management of a patient with OIH 1. The Big Picture • Practitioners often remark that use of opioids has become ubiquitous. The following slides show how common opioid prescribing has become, what the impetus was behind the shift in medical practice, and what are some of the unimagined consequences of a social movement that was not evidence-based. The existence of OIH has been recognized only after the impact of the right to pain treatment movement had its effect. Opioid Use Has Exploded! • 2009 USA, 5% of world’s population • 56% of global morphine • 81% of global oxycodone • 99% of global hydrocodone (Huxtable 2011) Opioid-Associated Deaths - USA • Year 1998 2005 • Oxycodone 14 1007 • Morphine 82 329 • Fentanyl 92 1245 • Methadone 8 329 (Huxtable 2011) “Pain Management: A Fundamental Human Right” “Reasons for deficiencies in pain management included cultural, societal, religious and political attitudes, including acceptance of torture.
    [Show full text]
  • Opioid Tolerance and Hyperalgesia
    Med Clin N Am 91 (2007) 199–211 Opioid Tolerance and Hyperalgesia Grace Chang, MD, MPH, Lucy Chen, MD, Jianren Mao, MD, PhD* Massachusetts General Hospital Pain Center, Division of Pain Medicine, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA Opioids are well recognized as the analgesics of choice, in many cases, for treating severe acute and chronic pain. Exposure to opioids, however, can lead to two seemingly unrelated cellular processes, the development of opi- oid tolerance and the development of opioid-induced pain sensitivity (hyper- algesia). The converging effects of these two phenomena can significantly reduce opioid analgesic efficacy, as well as contribute to the challenges of opioid management. This article will review the definitions of opioid toler- ance (particularly to the analgesic effects) and opioid-induced hyperalgesia, examine both the animal and human study evidence of these two phenom- ena, and discuss their clinical implications. The article will also differentiate the phenomena from other aspects related to opioid therapy, including physical dependence, addiction, pseudoaddiction, and abuse. Opioid tolerance and opioid-induced hyperalgesia Opioid tolerance is a phenomenon in which repeated exposure to an opi- oid results in decreased therapeutic effect of the drug or need for a higher dose to maintain the same effect [1]. There are several aspects of tolerance relevant to this issue [2]: Innate tolerance is the genetically determined sensitivity, or lack thereof, to an opioid that is observed during the first administration. Acquired tolerance can be divided into pharmacodynamic, pharmacokinetic, and learned tolerance [3]. Pharmacodynamic tolerance refers to adaptive changes that occur within systems affected by the opioid, such as opioid-induced changes in receptor density or desensitization of opioid receptors, such that response to a given * Corresponding author.
    [Show full text]
  • Package Leaflet: Information for the User Levomethadone Molteni 5 Mg
    Package leaflet: Information for the user Levomethadone Molteni 5 mg/ml oral solution Levomethadone hydrochloride Read all of this leaflet carefully before you start taking this medicine - because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Levomethadone Molteni is and what it is used for 2. What you need to know before you take Levomethadone Molteni 3. How to take Levomethadone Molteni 4. Possible side effects 5. How to store Levomethadone Molteni 6. Contents of the pack and other information 1. What Levomethadone Molteni is and what it is used for Levomethadone Molteni contains the active substance levomethadone hydrochloride. It belongs to a group of medicines which act on your nervous system. Levomethadone Molteni is used to treat adults who are addicted to drugs called ‘opioids’ or ‘narcotic analgesics’ - such as heroin and morphine. It acts as a substitute for the addictive drugs. 2. What you need to know before you take Levomethadone Molteni Do not take Levomethadone Molteni if: you are allergic to levomethadone or any of the other ingredients of this medicine (listed in section 6) you are taking medicines for depression called ‘MAOIs’ (monoamine oxidase inhibitors) or have taken them in the last 2 weeks (see ‘Other medicines and Levomethadone Molteni’) you are taking medicines to treat addiction or strong painkillers (see ‘Other medicines and Levomethadone Molteni’) you have severe breathing or lung problems you are not addicted to opioid drugs.
    [Show full text]
  • Methadone and Levomethadone: Risks and Costs Analyses
    METHADONE AND LEVOMETHADONE: PS-096, N07 RISKS AND COSTS ANALYSES Nora Pittet1, Isabella De Giorgi Salamun2, Olivier Simon3,4, Mohamed Hachaichi3, Eric Bergeron3, Mélanie Allaz2,3, Antoine Wildhaber3, Jacques Besson3, Farshid Sadeghipour1,2 1Section of pharmaceutical Sciences, University of Geneva, University of Lausanne; 2Pharmacy Service; 3Community Psychiatry, Lausanne University Hospital CHUV, Lausanne; 4Addiction Medicine College of Romandia COROMA, Switzerland . Background Conclusions • Racemic methadone oral solution 10mg/mL is the gold • This study allows the identification and quantification standard in the Opioid Agonist Treatment (OAT). of the main risks related to methadone and • Since recently, a levomethadone solution 5mg/mL is available levomethadone in our hospital. in Switzerland and will decrease the cardiac toxicity. • IM have been proposed taking into account the • However, the risk of errors and confusion in prescriptions, clinical and pharmacoeconomic aspects. preparation and administration seems to be significant and the • A cost-benefit analysis would be a perspective for a costs would be probably higher than the racemic solution. better assessment of the impact of levomethadone on Objectives morbidity/ mortality and the costs involved. • To analyse the risks of different dosage forms and Table 1: The 25 most critical FM products formulation from the prescription to the N° FM Who? CI administration of methadone and levomethadone in the 1 Error during hospital-outpatient transfer CHUV 343 2 Error of unit conversion AATC 336 Ambulatory Addiction Treatment Centre (AATC) and the 3 No double-check (or done by the patient only) CHUV 336 General Psychiatry. 4 Ambulatory-Hospital transmission by oral CHUV 294 5 Confusion between methadone and levomethadone bottles CHUV 294 • To assess the associated costs for the entire hospital.
    [Show full text]
  • <Product Name> 7.5 Mg Tablets 2. QUALITATIVE AND
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Product name> 7.5 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 6,7 mg levomethadone as 7.5 mg levomethadone hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Formal comment Information on the size of the tablet should be added. White to off-white, oblong, uncoated tablet with break scores on both sides, with a length of approximately 12 mm and a width of approximately 5.5 mm. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Severe pain in adults. 4.2 Posology and method of administration Levomethadone must be titrated individually. In general, the lowest effective analgesic dose should be chosen. The following recommended doses should be used as guidance. In case of severe pain conditions (e.g. cancer pain) doses may vary. It is recommended that the patient should rest during levomethadone’s duration of action. Posology Adults For adults a single dose of 7.5 mg levomethadone hydrochloride is recommended. In certain cases the initial dose might be 2.5 mg levomethadone hydrochloride. In case of decreasing efficacy administration can be repeated after 4-6 hours. In order to avoid a cumulative effect generally the second and all following doses should be lower than the initial dose. For the total daily dose it is recommended not to exceed 4 to 6 times the single dose. For the treatment of chronic pain administration following a fixed dose schedule should be preferred.
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Journal of Toxicology and Pharmacology Opioid Dependence
    Journal of Toxicology and Pharmacology Research Article Open Access levomethadone on μ receptors is 10 times higher than that of S-isomer Opioid Dependence Treatment: and that its analgesic potency, in humans, is about 50 times higher [3- is Levomethadone a New 5]. In healthy volunteers 7.5 mg of oral dextromethadone did not Frontier? A Pilot Study in Italy produce respiratory depression or pupillary constriction that were observed with an identical amount of levomethadone or with 15 mg of the racemic (R-S) methadone; a mild respiratory depression is observed Milo Meini1, Marco Moncini1, Laura Daini1, Daniela Scaramelli1, with dextromethadone in the dosage range of 50 to 100 mg [6,7]. Marta Milianti1, Tania Giarratana1 and Paola Rucci2* 1Local Health Authority Toscana Nordovest, Drug Addiction Service, Via In addition to exerting its action on opioid receptors, methadone Fleming 1, 56025 Pontedera (PI), Italy acts on glutamatergic receptors, and in particular on the N-methyl- 2Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum D-aspartate (NMDA) subtype of glutamate receptors. It has been University of Bologna, Via San Giacomo 12, 40126 Bologna, Italy hypothesized that the drug’s ability to induced less analgesic tolerance *Corresponding author: Paola Rucci, Email: [email protected] is due to the non-competitive antagonist action of S isomer at the NMDA receptors [1,8-12]. Received: 08 June 2017; Accepted: 01 September 2017; Published: 08 September 2017 Evidence from current international literature indicates that levomethadone is an active ingredient with improved safety profile and more efficacy than racemic; its pharmacodynamics would also allow Abstract the use of about half the dose [1,10,13,14].
    [Show full text]